The effect of rat acute-liver-failure plasma on HepaRG cells.

PURPOSE We recently demonstrated the high liver functionality of the human liver cell line HepaRG, including ammonia eliminating capacity, making it a valuable biocomponent of a bioartificial liver (BAL) to support patients with acute liver failure (ALF). This cell line further gains detoxification properties when cultured with dimethyl sulfoxide (DMSO). In this paper we describe whether its functionality is compromised by the toxic effects of ALF plasma, as has been shown for primary hepatocytes. METHODS We exposed -DMSO and +DMSO HepaRG cultures during 16 hours to healthy plasma and ALF-rat plasma. The cultures were analyzed for lipid accumulation, cell leakage, apolipoprotein A-1 production, nitrogen metabolism and transcript levels of hepatic genes. RESULTS The -DMSO cultures showed increased cell leakage after healthy and ALF plasma exposure in contrast to +DMSO cultures, but otherwise the -DMSO and +DMSO cultures were equally affected by exposure to the plasmas. Exposure to both plasmas caused lipid accumulation and decreased transcript levels of various hepatic genes. ALF plasma decreased urea cycle activity, but increased urea production from arginine by upregulated arginase 2. However, total ammonia elimination was not affected by exposure to either plasma, indicating its predominant elimination by fixation into amino acids. In addition, apolipoprotein A-1 production remained constant. CONCLUSIONS HepaRG cells are negatively affected by rat plasma, even of healthy origin. However, their ammonia eliminating capacity is relatively resistant, underlining their suitability for BAL application. DMSO pre-treatment may increase their viability in plasma.

[1]  P. Soeters,et al.  Fully automated liquid-chromatographic determination of amino acids. , 1988, Clinical chemistry.

[2]  A. Barbul,et al.  Arginine physiology and its implication for wound healing , 2003, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[3]  M. Matsushita,et al.  A hybrid artificial liver system. Function of cultured monolayer pig hepatocytes in plasma from hepatic failure patients. , 1991, ASAIO transactions.

[4]  R. Chamuleau,et al.  The HepaRG cell line is suitable for bioartificial liver application. , 2011, The international journal of biochemistry & cell biology.

[5]  J. Furui,et al.  Influence of Serum from Rats with Fulminant Hepatic Failure on Hepatocytes in a Bioartificial Liver System , 2004, The International journal of artificial organs.

[6]  P. Hayes,et al.  The Effect of Serum from Liver Cancer Patients on the Growth and Function of Primary and Immortalised Hepatocytes , 2001, The International journal of artificial organs.

[7]  M. Sosef,et al.  Treatment of Acute Liver Failure in Pigs Reduces Hepatocyte Function in a Bioartificial Liver Support System , 2002, The International journal of artificial organs.

[8]  P. Hayes,et al.  Improvement of C3A cell metabolism for usage in bioartificial liver support systems. , 2004, Journal of hepatology.

[9]  R. Tompkins,et al.  Long-term maintenance of cytochrome P450 activities by rat hepatocyte/3T3 cell co-cultures in heparinized human plasma. , 2001, Tissue engineering.

[10]  R. Tompkins,et al.  Effects of plasma exposure on cultured hepatocytes: Implications for bioartificial liver support , 2000, Biotechnology and bioengineering.

[11]  G. Mieli-Vergani,et al.  In Vitro Effects of Sera From Children With Acute Liver Failure on Metabolic and Synthetic Activity of Cryopreserved Human Hepatocytes , 2009, Journal of pediatric gastroenterology and nutrition.

[12]  C. Legallais,et al.  Artificial and bioartificial liver devices: present and future , 2009, Gut.

[13]  L. Nelin,et al.  Cytokine-induced arginase activity in pulmonary endothelial cells is dependent on Src family tyrosine kinase activity. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[14]  L. Flendrig,et al.  Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability. , 1999, Journal of hepatology.

[15]  S. Morris,et al.  Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. , 1998, American journal of physiology. Endocrinology and metabolism.

[16]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[17]  M. Grant,et al.  The effects of serum from patients with acute liver failure on the growth and metabolism of Hep G2 cells. , 1998, Artificial organs.

[18]  M. Grant,et al.  Cytotoxicity of bile in human Hep G2 cells and in primary cultures of rat hepatocytes. , 1998, Artificial organs.

[19]  G. Gores,et al.  Hepatocyte death: a clear and present danger. , 2010, Physiological reviews.

[20]  R. Hughes,et al.  Assay to Detect Inhibitory Substances in Serum of Patients with Acute Liver Failure , 1999, The International journal of artificial organs.

[21]  C. Degott,et al.  Microvesicular steatosis of the liver. , 1990, Acta clinica Belgica.

[22]  C. Selden,et al.  Modulation of hepatocyte function in an immortalized human hepatocyte cell line following exposure to liver-failure plasma. , 2002, Artificial organs.

[23]  P. Newsome,et al.  Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  B. Clement,et al.  Assessment of in vitro applicability of reversibly immortalized NKNT-3 cells and clonal derivatives. , 2006, Cell transplantation.

[25]  R. Hughes,et al.  Humoral inhibitor of rat hepatocyte DNA synthesis from patients with fulminant liver failure , 1994, Hepatology.

[26]  I. Díaz-Laviada,et al.  Morphological damage induced by Escherichia coli lipopolysaccharide in cultured hepatocytes: localization and binding properties. , 1988, British journal of experimental pathology.

[27]  C. Suschek,et al.  In hepatocytes the regulation of NOS-2 activity at physiological L-arginine levels suggests a close link to the urea cycle. , 2006, Nitric oxide : biology and chemistry.

[28]  M. Hesselink,et al.  Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids , 2001, Histochemistry and Cell Biology.

[29]  L. Corcos,et al.  Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. , 1993, Molecular pharmacology.

[30]  H. Heymans,et al.  Short-term protein intake and stimulation of protein synthesis in stunted children with cystic fibrosis. , 2005, The American journal of clinical nutrition.

[31]  R. Chamuleau,et al.  Stable overexpression of Pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  E. Drioli,et al.  The Effect of Catabolite Concentration on the Viability and Functions of Isolated Rat Hepatocytes , 1996, The International journal of artificial organs.

[33]  A. Thomson,et al.  The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. , 1976, British journal of experimental pathology.

[34]  P. Poyck,et al.  Increased reproducibility of quantitative reverse transcriptase-PCR. , 2005, Analytical biochemistry.

[35]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Olivier Fardel,et al.  Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  R. Chamuleau,et al.  Hepatic Encephalopathy and Artificial Liver Support Systems , 2006 .

[38]  R. Tompkins,et al.  Optimization of rat hepatocyte culture in citrated human plasma. , 2000, The Journal of surgical research.